Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.

ABSTRACT: Importance:Most studies that have examined drug prices have focused on list prices, without accounting for manufacturer rebates and other discounts, which have substantially increased in the last decade. Objective:To describe changes in list prices, net prices, and discounts for branded pharmaceutical products for which US sales are reported by publicly traded companies, and to determine the extent to which list price increases were offset by increases in discounts. Design, Setting, and Participants:Retrospective descriptive study using 2007-2018 pricing data from the investment firm SSR Health for branded products available before January 2007 with US sales reported by publicly traded companies (n = 602 drugs). Net prices were estimated by compiling company-reported sales for each product

SUBMITTER: Hernandez I 

PROVIDER: S-EPMC7054846 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature